2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

The 2026 AHA/ACC/ADA/ASN guideline updates and expands management strategies for cardiovascular-kidney-metabolic syndrome, targeting clinicians caring for affected patients.

• Why it matters: Addressing this interconnected syndrome is crucial because it involves multiple risk factors like obesity, diabetes, and kidney disease, which significantly impact patient outcomes.
• What they did: The guideline was developed through a comprehensive review of recent literature from 2015 to 2025, including clinical studies, systematic reviews, and meta-analyses, to inform current practice.
• The result: This living document aims to improve patient care by providing up-to-date, evidence-based recommendations for clinicians managing complex metabolic and cardiovascular conditions.